Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
about
Case-based study: from prediabetes to complications--opportunities for preventionFatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gammaNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewImplication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population.Treatment of prediabetesModulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modificationsMolecular targets of dietary polyphenols with anti-inflammatory propertiesEffects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK miceActivation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cellsInhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cellsLeptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic isletsCa(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazoneL-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand bindingTroglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasiaA human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugsIncreased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistanceAdiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeCocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension.Background and recruitment data for the U.S. Diabetes Prevention Program.Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment.The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders.From preadipocyte to adipocyte: differentiation-directed signals of insulin from the cell surface to the nucleus.Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers.Thiazolidinediones: a new class of antidiabetic drugs.Further understanding of fat biology: lessons from a fat flyEndothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress.Current therapeutic options in type 2 diabetes.LDL particle size: an important drug target?Morinda citrifolia Linn. (Noni) and Its Potential in Obesity-Related Metabolic Dysfunction.Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity.PPARs in the Renal Regulation of Systemic Blood PressureCellular retinol-binding protein type I (CRBP-I) regulates adipogenesis.Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene.The glitazones: proceed with caution.Pharmacotherapy of type 2 diabetes mellitus.Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonistsPhosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women.Sequence variation in PPARG may underlie differential response to troglitazone.
P2860
Q21144738-FF10CBB2-C926-4A0F-9A0E-431F7C810ADDQ24314755-7A58772A-5F00-4F24-A425-6DCE40AE78AEQ24561401-9FB86593-2DAB-4005-A5E6-0182005A070AQ24791420-C96369FF-6B3A-4E09-AC4A-006925DC7544Q26783350-78D340DA-8606-4121-ADE1-F36EA7365123Q27015807-82E280B7-D2AE-4A3F-9158-82C15ADF9F05Q28192995-7F90032F-1A4A-4D48-93D9-34A05A08E16BQ28204609-C76481A3-F4AA-4070-A751-76D1A5F601A7Q28214426-C4752E75-3349-4C53-8842-DE41C9E63B97Q28343969-C0C6AD81-FB82-4597-A0BD-DE3528CAD22EQ28344493-32805AFD-B506-4781-839D-F4D4EF094E97Q28345773-FFD43C33-2C8D-4D26-843E-732115058B94Q28371591-36BEB946-FBA8-491E-9C13-DBC7FE84FF67Q28379241-C45EC135-C5C0-40E7-AD9B-D265A79CDA7DQ28609826-B4FD8352-AAF2-4CB7-B22A-3485CD7BBB30Q29012156-9E605BCC-2F9E-4228-988C-B0944403CB79Q29619211-427043C2-9DDD-48B6-BD76-D9E898E596CCQ30434226-FCA70158-9CAD-4FB9-BDA1-55A5BF65EAEFQ30597884-63C9779E-AC1E-45F9-9CCD-B30E1BED7A6DQ32016616-30D18A2A-58BD-49B2-AF2C-D62B5CF99B87Q33537653-CBCC8657-51E3-4A8F-B0F0-BE823C3FB508Q33545583-1630773F-3C6E-45E0-91AD-94F37D885E01Q33600223-444752E3-F211-4ADB-880B-B12F654B3659Q33607634-D16E664E-3A30-423E-833D-B852F1928E8DQ33612304-8D097094-4E3C-4ED9-88AA-5B77C44EBDDCQ33642053-F8447617-5AF4-4868-8404-C013608D3A95Q33642761-373DE5DF-91B8-4C33-9BAE-9815278A6C01Q33670815-7AF61A54-617A-43EF-93F3-4E580D19E21FQ33693960-C1ECE3C1-FB6A-448D-85F0-3CB7CCECC591Q33851783-08CBD3EB-BE80-417C-9829-A5026A6D58CDQ33869780-3715F4DB-31C0-4CAA-A86E-4A485FB63EF1Q33960908-A1639C1D-4695-47EB-9941-710DE04CF907Q33963887-5572A77E-B378-4B9A-82CA-1DB9288BF0CFQ33964333-27306CC9-69D3-4964-85F1-15D7BBB8FF5BQ33973778-928A225D-C144-48DF-A4B7-1BB95D5C4058Q33992531-A1E153B9-565A-415E-946C-888F8EE7F67CQ34011043-62D2C302-F08C-422F-B0CA-65AD74AE08D6Q34024181-4151FB86-713A-40F6-8310-4BF0699B0B71Q34024266-0EA4659D-EE93-4B3D-80BA-9F54220B6C9BQ34072562-3C8C32AB-9CCC-481A-8534-212B3741A2BE
P2860
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
description
1994 nî lūn-bûn
@nan
1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Improvement in glucose toleran ...... cts treated with troglitazone.
@ast
Improvement in glucose toleran ...... cts treated with troglitazone.
@en
Improvement in glucose toleran ...... cts treated with troglitazone.
@nl
type
label
Improvement in glucose toleran ...... cts treated with troglitazone.
@ast
Improvement in glucose toleran ...... cts treated with troglitazone.
@en
Improvement in glucose toleran ...... cts treated with troglitazone.
@nl
prefLabel
Improvement in glucose toleran ...... cts treated with troglitazone.
@ast
Improvement in glucose toleran ...... cts treated with troglitazone.
@en
Improvement in glucose toleran ...... cts treated with troglitazone.
@nl
P2093
P921
P1476
Improvement in glucose toleran ...... cts treated with troglitazone.
@en
P2093
P304
P356
10.1056/NEJM199411033311803
P407
P577
1994-11-01T00:00:00Z